Triple attack on pancreatic cancer shows promise in early trial
NCT ID NCT02648282
First seen Mar 18, 2026 · Last updated May 23, 2026 · Updated 17 times
Summary
This study tested a combination of a pancreatic cancer vaccine (GVAX), an immunotherapy drug (pembrolizumab), and focused radiation (SBRT) in 58 people with locally advanced pancreatic cancer. The goal was to see if this mix could delay the spread of cancer to other parts of the body. Participants had already received standard chemotherapy before joining.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Sidney Kimmel Comprehensive Cancer at Johns Hopkins
Baltimore, Maryland, 21231, United States
Conditions
Explore the condition pages connected to this study.